Oragenics Inc (NYSEAMERICAN:OGEN) shares gapped up before the market opened on Tuesday . The stock had previously closed at $0.60, but opened at $0.57. Oragenics shares last traded at $0.57, with a volume of 14,806 shares traded.
Separately, HC Wainwright set a $2.00 price target on Oragenics and gave the stock a “buy” rating in a research report on Friday, August 16th.
Oragenics (NYSEAMERICAN:OGEN) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03).
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Further Reading: How Investors Can Profit from Options Trading
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.